Takumi Nakada
Gifu-shi, 5008513, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study.
Journal: Journal of Cancer
Published: June 14, 2023
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Journal: Breast cancer (Tokyo, Japan)
Published: August 19, 2022
Analysis of Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in Our Department
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: November 02, 2018
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: February 02, 2018
Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast Cancer.
Journal: Journal of pharmaceutical health care and sciences
Published: December 14, 2017
Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Journal: Breast cancer (Tokyo, Japan)
Published: July 15, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026